Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Genesys Capital

Founders Damian Lamb Kelly Holman

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 35
Average round size
info
The average size of a deal this fund participated in
$26M
Portfolio companies 23
Rounds per year 1.46
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.34
Exits 6
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

Genesys Capital is the famous VC, which was founded in 2000. The company was established in North America in Canada. The leading representative office of defined VC is situated in the Toronto.

This organization was formed by Damian Lamb, Kelly Holman. The overall number of key employees were 4.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical Device, Medical. Among the most popular portfolio startups of the fund, we may highlight Fusion Pharmaceuticals, Tioga Pharmaceuticals, NeurAxon. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. The fund has exact preference in some founders of portfolio startups. If startup sums 3 of the founder, the chance for it to be financed is low.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Genesys Capital, startups are often financed by Adams Street Partners, TPG Biotech, PathoCapital. The meaningful sponsors for the fund in investment in the same round are Adams Street Partners, TPG Biotech, PathoCapital. In the next rounds fund is usually obtained by OrbiMed, Adams Street Partners, Varian Medical Systems.

Considering the real fund results, this VC is 10 percentage points less often commits exit comparing to other organizations. Opposing the other organizations, this Genesys Capital works on 14 percentage points less the average amount of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2015. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Genesys Capital:
Typical Co-investors
Genesys Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Genesys Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Canada
Funds with similar focus located in Canada:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aflac Columbus, Georgia, United States
Allstate Strategic Ventures Illinois, Northbrook, United States
Altatech France, Montbonnot-saint-martin, Rhone-Alpes
Analog Devices Massachusetts, Norwood, United States
BayStartUP Bavaria, Germany, Nuremberg
DIP Capital England, London, United Kingdom
High Rise Ventures Berlin, Berlin, Germany
Ipanema Technologies Courceboeufs, France, Pays de la Loire
Joyance Partners California, San Francisco, United States
Leksell Social Ventures -
Neoforma California, San Jose, United States
Quantum Leap for Technology Co. -
Shanghai Shanrui Investment China, Shanghai
Shanghai Xuntian Investment China, Shanghai
Shenzhen Qianhai Zhongyinhui Investment Management China, Guangdong, Shenzhen
Silicom Ventures California, Los Altos, United States
Steinbeis -
Vigo Activo Galicia, Nigrán, Spain
Wensu Investment -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Feldan Therapeutics

Biotechnology
Therapeutics
$21M04 Sep 2024 Quebec City, Quebec, Canada

Flosonics

Health Care
Medical
Medical Device
$20M19 Mar 2024 Greater Sudbury, Ontario, Canada

Inversago Pharma

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$75M17 Oct 2022 Montreal, Quebec, Canada

Veralox Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$16M16 Jun 2021 Frederick, Maryland, United States

Giiant Pharma

Biopharma
Biotechnology
Health Care
Life Science
$11M21 May 2021 Montréal, Quebec, Canada

Inversago Pharma

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$35M08 Sep 2020 Montreal, Quebec

IDbyDNA

Biotechnology
Health Care
Life Science
$20M29 Jan 2020 California, United States

EBT Medical

Health Care
Medical Device
$10M19 Nov 2019 Ontario

Fusion Pharmaceuticals

Biopharma
Biotechnology
Clinical Trials
Medical
Pharmaceutical
$105M01 Apr 2019 Hamilton, Ontario, Canada
News
Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept

– Giiant Pharma inc. announced that is closed an additional financing of $750,000 from AQC Capital and $500,000 from CQDM for a total of $1.25 million.
– The preclinical-stage biotech Company’s also closed a Seed round of $13.5 million, co-led by Amplitude Ventures and Genesys Capital.
– This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.
– Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. The team is also in active discussions with potential partners to expand its pipeline of precisely delivered drug therapeutics for gastrointestinal disease.

Veralox Therapeutics Closes $16.6M Series A Financing

– Veralox is a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, closed a $16.6m Series A financing.
– The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments as well as support from previous investors Sanofi Ventures, JDRF T1D Fund, Maryland Momentum Fund, VTC Innovation Fund and TEDCO.
– The new investment will be used to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Genesys Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 35
Average round size 26M
Rounds per year 1.46
Peak activity year 2017
Lead investments 4
Follow on index 0.34
Exits 6
Group Appearance index 0.94

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Feldan Therapeutics

Biotechnology
Therapeutics
$21M04 Sep 2024 Quebec City, Quebec, Canada

Flosonics

Health Care
Medical
Medical Device
$20M19 Mar 2024 Greater Sudbury, Ontario, Canada

Inversago Pharma

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$75M17 Oct 2022 Montreal, Quebec, Canada

Veralox Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$16M16 Jun 2021 Frederick, Maryland, United States

Giiant Pharma

Biopharma
Biotechnology
Health Care
Life Science
$11M21 May 2021 Montréal, Quebec, Canada

Inversago Pharma

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$35M08 Sep 2020 Montreal, Quebec

IDbyDNA

Biotechnology
Health Care
Life Science
$20M29 Jan 2020 California, United States

EBT Medical

Health Care
Medical Device
$10M19 Nov 2019 Ontario

Fusion Pharmaceuticals

Biopharma
Biotechnology
Clinical Trials
Medical
Pharmaceutical
$105M01 Apr 2019 Hamilton, Ontario, Canada
Crunchbase icon

Content report

The following text will be sent to our editors: